<DOC>
	<DOCNO>NCT00956982</DOCNO>
	<brief_summary>The purpose study analyze efficacy safety combination therapy pegylated interferon ( PEG-IFN ) alpha-2b plus ribavirin ( RBV ) old Japanese patient ( ≧65years old ) infect hepatitis C virus ( HCV ) compare young patient ( &lt; 65 year old ) .</brief_summary>
	<brief_title>PEG-IFN Plus Ribavirin Combination Therapy Older Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>A prospective study 2270 Japanese patient age 18 year older treat PEGIFN alpha2b plus RBV do December 2004 July 2008 . All positive antibody HCV HCVRNA six month enrol . Clinical biochemical evidence hepatic decompensation . Advanced cirrhosis identify large esophageal varix ( F2 F3 ) . History gastrointestinal bleeding , ascites , encephalopathy , hepatocellular carcinoma . Hemoglobin level &lt; 11.5g/L , white blood cell count &lt; 3×10９/Ｌ，and platelet count &lt; 50×10９/Ｌ . Concomitant liver disease hepatitis C ( hepatitis B surface antigen positive HIV positive ) . Excessive active alcohol consumption &gt; 60 g/day drug abuse . Severe psychiatric disease . Antiviral corticosteroid therapy within 12 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Hepatitis C Virus Pegylated Interferon Ribavirin Older</keyword>
</DOC>